Bizarre Patents
A new toilet tank assembly aquarium for housing aquatic creatures.
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7435407 | Inhibition of olfactory neurosensory function to treat eating disorders and obesity The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical compo... | 10/14/2008 |
| 7425577 | Lipase-colipase inhibitor The present invention relates to novel colipase-lipase inhibitors of the general formulae to be used in the treatment of prophylaxis of obesity, as well as pharmaceutical compositions containing the same, and method for treating obesity using said compounds. ... | 09/16/2008 |
| 7422764 | Matrix-forming composition containing pectin A liquid edible composition with a pH of more than 6, a viscosity below 600 mPas at a shear rate of 100s-1 and 20° C., and a viscosity of at least 125% of the aforementioned viscosity at a pH below 5 and a temperature of 37° C., the composition comprising at least... | 09/09/2008 |
| 7422763 | Acid controlled induced viscosity fiber system and uses thereof The present invention relates generally to a method of blunting the postprandial glycemic response to a meal by feeding an acid controlled induced viscosity fiber system. The first component of the induced viscosity fiber system is anionic soluble fiber. The second ... | 09/09/2008 |
| 7419951 | Method of reducing adipocyte growth in a subject in need thereof by administration of natriuretic peptide receptor C inhibitors Disclosed is a method of using synthetic analogs of natriuretic peptides and more particularly to synthetic linear peptide analogs as pro-lipolytic, as anti-obesity agents, and as intermediates for or modulators of such useful compounds. Inhibitors to nprC are discl... | 09/02/2008 |
| 7300675 | Lipolysis stimulator A lipolysis stimulator and a slimming agent which stimulate or facilitate lipolysis of accumulated adipose tissue, to thereby exert the body slimming effect. The lipolysis stimulator or the slimming agent of the present invention contains as an active ingredient any... | 11/27/2007 |
| 7271153 | Nitrogenous heterocyclic derivatives, medicinal compositions containing the same, medicinal uses thereof, and intermediates therefor The present invention provides nitrogen-containing heterocyclic derivatives represented by the general formula: wherein X1 and X3 independently represent N or CH; X2 represents N ... | 09/18/2007 |
| 7268161 | Comprehensive pharmacologic therapy for treatment of obesity including cysteine The comprehensive pharmacologic therapy for treatment of obesity including Cysteine is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and/or Phentermine in combination with a SSRI medication and nutritional supplementa... | 09/11/2007 |
| 7229965 | Use of growth hormone in low dose The invention relates to treatment of patients in need of increasing insulin sensitivity by administration of growth hormone or analogues thereof, preferably human growth hormone, in a low dose and the use of growth hormone or analogues thereof, preferably human gro... | 06/12/2007 |
| 7223727 | GSSP4 polynucleotides and polypeptides and uses thereof The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabol... | 05/29/2007 |
| 7214778 | Glycoprotein with antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects from , and a method for preparing same A glycoprotein extracted from the fruiting body of Grifola frondosa is demonstrated to have antidiabetic, antihypertensive, antiobesity and antihyperlipidemic effects, and has great potential as an active component for pharmaceuticals, dietary supplements or ... | 05/08/2007 |
| 7211557 | Use of GLP-1 analogs and derivatives administered peripherally in regulation of obesity This invention relates the use of glucagon-like peptides such as GLP-1, a GLP-1 analog, or a GLP-1 derivative in methods and compositions for reducing body weight. ... | 05/01/2007 |
| 7199160 | Antiobestic agents and health foods Antiobestic agents and health foods containing as the active ingredient substances having an effect of adsorbing bile acid in the digestive tract, an effect of inhibiting intestinal circulation or an effect of inhibiting the absorption of exogenous lipids typified b... | 04/03/2007 |
| 7175859 | Plant extract mixtures and their uses A composition comprising extract of one or more plants of one or more of the following plant families: Cissus, Vernonia and Brillantasia. Such compositions have beneficial activity principally in controlling weight gain and obesity, especially in conju... | 02/13/2007 |
| 7160924 | Protein conjugates with a water-soluble biocompatible, biodegradable polymer The present invention broadly relates to the field of protein modification, and, more specifically, to conjugates of proteins or analogs thereof to a water-soluble biocompatible polymer and methods of making and using the same. ... | 01/09/2007 |
| 7153877 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bo... | 12/26/2006 |
| 7138107 | Inhibition of olfactory neurosensory function to treat eating disorders and obesity The use of calcium channel blockers administered intra-nasally to inhibit olfactory sensory perception to treat eating disorders, including obesity, is described. Also described is a method of reducing food intake in a subject by administering a pharmaceutical compo... | 11/21/2006 |
| 7122209 | Oral compositions for the treatment of non-diabetic obese mammals, including humans Oral compositions containing an effective amount of a tungsten compound (VI), preferably a tungstate salt, more preferably sodium tungstate (Na2WO4), are useful in controlling obesity/overweightness in non-diabetic mammals, including humans. Th... | 10/17/2006 |
| 7119110 | Method and composition for preventing or reducing the symptoms of insulin resistance syndrome A method for preventing and or reducing the symptoms of insulin resistance and a related syndrome in persons comprises identifying persons having or at risk for having such symptoms, and administering to them an effective amount of a composition comprising niacin-bo... | 10/10/2006 |
| 7115575 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1... | 10/03/2006 |
| 7101838 | Method to prevent accelerated atherosclerosis using (sRAGE) soluble receptor for advanced glycation endproducts The present invention provides for a method to prevent accelerated atherosclerosis in a subject predisposed thereto which comprises administering to the subject a polypeptide derived from soluble receptor for advanced glycation endproduct in an amount effective to p... | 09/05/2006 |
| 7094763 | Substituted fused heterocyclic C-glycosides This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X. ... | 08/22/2006 |
| 7067498 | Polymer controlled induced viscosity fiber system and uses thereof The present invention relates generally to a method of blunting the postprandial glycemic response in a human by feeding an induced viscosity fiber system. The invention also relates to an induced viscosity fiber system and the liquid products that incorporate the i... | 06/27/2006 |
| 7056892 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1... | 06/06/2006 |
| 7048917 | Fat-binding polymers The present invention relates to a method for treating obesity, a method for reducing the absorption of dietary fat, and a method for treating hypertriglyceridemia in a patient and to particular polymers for use in the methods or in a manufacture of a medicament. Th... | 05/23/2006 |
| 6989165 | Synergistic composition for treating hyperilipdemia The present invention relates to a synergistic pharmaceutical composition useful for the treatment of hyperlipidemia, said composition comprising extracts of plant Gentiana kurroo of concentration ranging between 2–5 wt. %, Murraya koenigii of concen... | 01/24/2006 |
| 6989367 | OBG3 globular head and uses thereof The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body... | 01/24/2006 |
| 6972283 | Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof The present invention relates to glucopyranosyloxypyrazole derivatives represented by the general formula: wherein R1 represents a hydrogen atom or a lower alkyl group; one of Q1 and T1 | 12/06/2005 |
| 6960300 | Process for preparing water soluble diterpenes and their applications Aqueous solutions of diterpenes such as Forskolin, its congeners, analogs and derivatives, up to approximately 6% concentration, are prepared using suitably substituted cyclodextrin as a solubilizing agents. In the absence of cyclodextrin, some diterpenes such as Fo... | 11/01/2005 |
| 6903657 | System and method of performing medical diagnosis in real time A system and method of performing a medical diagnosis in real time that can diagnose a health condition of a mobile terminal user in real time is disclosed. Various sensors provided in the mobile terminal sense a body condition, and a server diagnoses the health con... | 06/07/2005 |
| 6896909 | Formulations containing iron ores for the topical treatment of bioenergetic and electromagnetic disorders The invention relates to formulations for the topical treatment of disorders with a bioenergetic basis, which contain a suspension obtainable by treating one or more iron ores with aqueous solutions having pH values of between 4 and 8. These formulations will be app... | 05/24/2005 |
| 6875428 | Lipase inhibiting polymers The invention features a method for treating obesity in a patient by administering to the patient a polymer that has been substituted with one or more groups that inhibit lipases, which are enzymes responsible for the hydrolysis of fat. The invention further relates... | 04/05/2005 |
| 6863904 | Compositions and methods for prophylactic and therapeutic supplementation of nutrition in subjects The present invention relates to compositions without added iron and methods for prophylactic nutritional supplementation and therapeutic nutritional supplementation. Specifically, the method involves administering to an individual a composition comprising carotenoi... | 03/08/2005 |
| 6861073 | Dysfunctional satiety center syndrome and method of treatment therefor The present invention provides a method of treating obesity in mammals, particularly humans. The method comprises the step of administering a dietary supplement that includes about 25 mg to about 10 g calcium carbonate precipitate; about 25 mg to about 10 g coral ca... | 03/01/2005 |
| 6852342 | Compounds for altering food intake in humans The present invention relates to a process of providing an extract containing at least one simmondsin compound. The extract is provided from jojoba plant, and used as a dietary supplement for use in a weight control regiment in humans. The present invention also pro... | 02/08/2005 |
| 6844021 | Oil or fat composition The oil or fat composition of the invention contains a monoacylglycerol and/or a diacylglycerol in a total amount of 5-100 wt. % and which exhibits an index of stability against oxidation (induction time as measured through a Rancimat test conducted at 100° C.) of ... | 01/18/2005 |
| 6831105 | Compositions comprising ether compounds and pharmaceutical uses therefor The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a compo... | 12/14/2004 |
| 6825209 | Compounds having unique CB1 receptor binding selectivity and methods for their production and use Compounds are provided that are amide analogs of SR141716A having unique CB1 receptor selectivity and providing WIN sparing binding characteristics, pharmaceutical compositions containing the compounds and their use in a method of treatment of CB1 receptor related d... | 11/30/2004 |
| 6815417 | Method for treating obesity and for inhibiting adipocyte activity A method for treating obesity includes administering to humans or animals a pharmaceutically effective amount of stanniocalcin in the form of a pharmaceutical composition. Stanniocalcin has an excellent activity of inhibiting the differentiation and maturation of ad... | 11/09/2004 |
| 6797283 | Gastric retention dosage form having multiple layers The present invention is directed to a multilayered dosage form which is adapted for retention in the stomach and useful for the prolonged delivery of an active agent to a fluid environment of use. The active agent dosage form is a multilayer core, often bilayer, fo... | 09/28/2004 |